23 research outputs found
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial
AbstractThrombolysis of acute pulmonary embolism can be accomplished more rapidly and safely with 100 mg of recombinant human tissue-type plasminogen activator (rt-PA) (Activase) than with a conventional dose of urokinase (Abbokinase) given as a 4,400-U/kg bolus dose, followed by 4,400 U/kg per h for 24 h. To determine the effects of a more concentrated urokinase dose administered over a shorter time course, this trial enrolled 90 patients with baseline perfusion lung scans and angiographically documented pulmonary embolism. They were randomized to receive either 100 mg/2 h of rt-PA or a novel dosing regimen of urokinase: 3 million U/2 h with the initial 1 million U given as a bolus injection over 10 min. Both drugs were delivered through a peripheral vein.To assess efficacy after initiation of therapy, repeat pulmonary angiograms at 2 h were performed in 87 patients and then graded in a blinded manner by a panel of six investigators. Of the 42 patients allocated to rt-PA therapy, 79% showed angiographic improvement at 2 h, compared with 67% of the 45 patients randomized to urokinase therapy (95% confidence interval for the difference in these proportions [rt-PA minus urokinase] is â6.6% to 30.4%; p = 0.11). The mean change in perfusion lung scans between baseline and 24 h was similar for both treatments. Three patients (two treated with rt-PA and one with urokinase) had an intracranial hemorrhage, which was fatal in one.The results indicate that a 2-h regimen of rt-PA and a new dosing regimen of urokinase exhibit similar efficacy and safety for treatment of acute pulmonary embolism
Phase III Study of PSC-833 (Valspodar) in Combination with Vincristine, Doxorubicin, and Dexamethasone (Valspodar/VAD) versus VAD Alone in Patients with Recurring or Refractory Multiple Myeloma (E1A95)
BACKGROUND. Preliminary studies have shown valspodar (PSC-833: Novartis Pharmaceuticals,
East Hanover, NJ) to be a potent inhibitor of multidrug resistance
(MDR), one cause of resistance to chemotherapy. An international randomized
control study (Phase III) evaluated the use of vincristine, doxorubicin, and dexamethasone
(VAD) with (n 46) and without (n 48) valspodar in the treatment of
patients with recurring or refractory multiple myeloma.
METHODS. Patients with documented recurrence or refractory myeloma were stratified
based on prior treatment exposure and creatinine and randomized. Because
of interaction of valspodar with vincristine and doxorubicin, the doses of these
drugs were reduced compared with the VAD-alone arm, and the doxorubicin was
further reduced in the last 15 patients when given with valspodar based on
pharmacokinetic and toxicity studies.
RESULTS. There were no complete or near-complete responses. There were 29%
partial responses (PRs) in the VAD-alone arm and 44% with valspodar (P 0.2).
Median progression-free survival was 7 months with VAD alone and 4.9 months
with valspodar (P 0.50). Subjective response was 19% with VAD alone and 17%
with valspodar (P 1.0). Median survival with VAD alone was 18.5 months and
15.3 with the addition of valspodar (P 0.055). Toxicity of Grade 3 or greater
was higher (P 0.0001) in the valspodar arm (89%) compared with the VAD-alone
arm (58%). The reduction of doxorubicin dose reduced toxicity but not significantly
(P 0.11).
CONCLUSION. The addition of the MDR-modulating agent valspodar to VAD did not
improve treatment outcome. Toxicity was increased in the valspodar-treated group
compared with VAD alone
Dynamic detection and reversal of myocardial ischemia using an artificially intelligent bioelectronic medicine
Potentially damaging âheart stressâ is reversed using reactive nerve stimulation controlled by artificial intelligence.
Myocardial ischemia is spontaneous, frequently asymptomatic, and contributes to fatal cardiovascular consequences. Importantly, myocardial sensory networks cannot reliably detect and correct myocardial ischemia on their own. Here, we demonstrate an artificially intelligent and responsive bioelectronic medicine, where an artificial neural network (ANN) supplements myocardial sensory networks, enabling reliable detection and correction of myocardial ischemia. ANNs were first trained to decode spontaneous cardiovascular stress and myocardial ischemia with an overall accuracy of ~92%. ANN-controlled vagus nerve stimulation (VNS) significantly mitigated major physiological features of myocardial ischemia, including ST depression and arrhythmias. In contrast, open-loop VNS or ANN-controlled VNS following a caudal vagotomy essentially failed to reverse cardiovascular pathophysiology. Last, variants of ANNs were used to meet clinically relevant needs, including interpretable visualizations and unsupervised detection of emerging cardiovascular stress. Overall, these preclinical results suggest that ANNs can potentially supplement deficient myocardial sensory networks via an artificially intelligent bioelectronic medicine system